Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Tianyin Pharmaceutical Co. Inc. Stories

2014-02-14 00:21:14

CHENGDU, China, Feb. 14, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter fiscal year 2014. Second Quarter Fiscal 2014 Ended December 31, 2013 Financial Highlights: -- Revenue was $13.9 million versus $17.6 million in the second...

2014-02-09 16:21:05

CHENGDU, China, Feb. 9, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the second quarter of fiscal year 2014 ended December 31, 2013 to be held at 9:00 a.m. ET on Friday, February 14(th), 2014. Interested parties may...

2013-11-11 04:21:22

CHENGDU, China, Nov. 11, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the first quarter of fiscal year 2014 ended September 30, 2013 to be held at 8:30 a.m. ET on Friday, November 15(th), 2013. Interested...

2013-10-15 00:20:43

CHENGDU, China, Oct. 15, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), announced that as of October 8, 2013, the Audit Committee and the Board of Directors of TPI (the "Company") both unanimously approved the termination of the Company's independent auditor, Patrizio and Zhao LLC...

2013-09-19 04:21:09

CHENGDU, China, Sept. 19, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the fiscal year 2013 ending June 30, 2013 to be held at 9:00 a.m. ET on Friday, September 27(th), 2013. Interested parties may access the call...

2013-09-12 12:28:58

CHENGDU, China, Sept. 12, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company has received the Official Certificate of GMP for both of its pre-extraction plant and formulate facilities. TPI manufacturing facilities including its pre-extraction...

2013-08-15 12:29:47

CHENGDU, China, Aug. 15, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided the updates regarding TPI's manufacturing (pharmaceutical formulation) facility. TPI manufacturing facility, located at Longquan County of Chengdu, has been awarded the GMP renewal status for...

2013-07-19 04:21:35

CHENGDU, China, July 19, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided further updates on the business development of its flagship product: Gingko Mihuan Oral Liquid (GMOL) with the SFDA approval number: H20013079. GMOL is a prescription medicine that targets...

2013-07-14 08:21:33

CHENGDU, China, July 14, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updated its corporate presentation with macrolide antibiotics API market information: Jiangchuan Pharmaceutical: 87% owned by TPI, to produce Active Pharmaceutical Ingredients (API) of macrolide...

2013-07-02 08:25:51

CHENGDU, China, July 2, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided the updates regarding TPI's Qionglai Facility (QLF). QLF, after the completion of its construction in April, has entered the phase for equipment installation. QLF staff also conducted a series...